New generation cancer therapy: right direction for sure with some uncertainty
The recent case report by Zacharakis et al. highlights the overwhelming effectiveness of sophisticated cancer immunotherapy along with immune checkpoint inhibitors . The use of this logical approach helped a patient recover completely from advanced breast cancer, as planned by the researchers. This is one of the most famous case reports to date, signifying the landmark triumph of modern anti-cancer immunotherapy. Cancer immunotherapy was theoretically introduced in the early 1980s or even earlier. However, because of their limited clinical effectiveness, the first-generation cancer immunotherapy did not prevail in the clinical settings. Conversely, the advancement in the understanding of the mechanism of T cell activation has further enabled the development of immune checkpoint inhibitory drugs. Notably, anti-CTLA-4 antibody (ipilimumab) and anti-PD-1 antibodies (pembrolizumab and nivolumab) are already approved for the treatment of various solid tumors. For the treatment of...
Compliance with ethical standards
Conflict of interest
The author does not have any potential conflict of interest regarding this article.
Human and/or animals rights
This article is not applicable to document approval from IRB for research involving human participants and/or animals, and statement regarding obtaining informed consent.
- 19.Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight 2018; 3(7). https://doi.org/10.1172/jci.insight.99573
- 20.Beasley D. The cost of cancer: new drugs show success at a steep price. Reuters. 2017 April 3 2017; Sect. Health News. URL http//www.reuters.com/article/us-usa-healthcare-cancer-costs/the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-idUSKBN1750FU. Accessed 1 July 2018
- 21.Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 2017; 9(403). https://doi.org/10.1126/scitranslmed.aan2415